With the 2024 AusBiotech and #AusBioInvest2024 completed, we’re thrilled to reflect on the incredible outcomes. As Australia's premier #biotech investment event, AusBioInvest2024 we: 🔹 welcomed over 330 delegates in Melbourne. 🔹 heard from 23 biotech companies - from early-stage startups to more advanced ventures and publicly listed companies - pitching cutting-edge innovations and growth potential. 🔹 held 89 partnering meetings that laid the foundation for future partnerships and investments. Congratulations to the #Victorian companies on delivering impactful pitches that showcased their groundbreaking innovations, world-leading talent and capabilities. Here’s a snapshot of their work: 👉 Amplia Therapeutics Limited: Pioneering the development of targeted drug therapy through clinical development of two potent, orally available Focal Adhesion Kinase inhibitors intended to treat cancer and fibrotic diseases. 👉 Arovella Therapeutics ASX: ALA: Innovating in immunotherapy. Their cutting-edge cell therapy platform is set to transform treatments for blood cancers and solid tumours. 👉 Atticus Medical: Developing treatments for infectious diseases that heavily impact socially and financially disadvantaged communities. 👉 Chimeric Therapeutics: Developing an innovative approach to advanced cell therapies. Their focus on clinical-stage programs and diversifying treatment options for cancer patients positions them as leaders in bringing new cell-based therapies into the market. 👉 Esfam Biotech: Developing small-molecule therapies targeting oncology and other critical health issues. Their products aim to address unmet medical needs in cancer care, offering treatments that are more effective, affordable, and better tolerated by patients, ultimately improving patient outcomes and quality of life. 👉 Immuron: Developing orally delivered treatments using proprietary technology to target enteric pathogens. This creates highly specific immunoglobulins, offering a unique solution for gastrointestinal diseases. 👉 Invion Limited: Developing the nextgen Photodynamic Therapy, for the treatment of a range of cancers and infectious diseases. Their innovative treatment offers a less invasive, highly targeted alternative to surgery, with minimal side effects. 👉 Neurizon: Advancing treatments for neurodegenerative diseases. Currently developing its lead drug candidate for treatment of ALS, the most common form of motor neurone disease. 👉 PolyActiva: Pioneering ophthalmic sustained drug delivery to enhance patient outcomes and quality of life. Victoria was honoured to host this year’s AusBioInvest and #AusBiotech events in Melbourne, welcoming attendees from around the world to connect in our amazing city. Learn more about how we can assist you invest in Victoria’s health sector. https://lnkd.in/g-JJ8q6 #ThinkMelbourne #LifeSciences #Innovation
-
+4